Get started

Pfizer_buy

Pfizer Stock Rises on Report Starboard Takes $1Bln StakePfizer Inc. (NYSE: NYSE:PFE ), once a market darling during the COVID-19 pandemic thanks to its breakthrough vaccine, has seen its stock struggle over the past two years. The shares are trading roughly 30% lower than in 2019 and have faced immense pressure due to declining demand for its COVID-related products and a costly acquisition strategy. However, a new catalyst has emerged that may signal a turning point for the pharmaceutical giant—activist investor Starboard Value has reportedly taken a $1 billion stake in Pfizer (NYSE: NYSE:PFE ), setting the stage for a potential turnaround. Let's dive into the technical and fundamental aspects driving this story. A Billion-Dollar Vote of Confidence Starboard Value's stake in Pfizer (NYSE: NYSE:PFE ), valued at roughly $1 billion, is a clear signal that the activist hedge fund believes there is untapped value in the company. Starboard has a track record of targeting underperforming companies and pushing for strategic changes to unlock shareholder value. This time, Starboard appears to be focusing on Pfizer’s management, specifically CEO Albert Bourla, who has been criticized for his acquisition-heavy strategy since taking the helm in 2019. Under Bourla, Pfizer (NYSE: NYSE:PFE ) has spent close to $70 billion on acquisitions, including the $43 billion deal for Seagen in 2022, focused on cancer drugs. While Pfizer (NYSE: NYSE:PFE ) hoped these moves would diversify its revenue streams beyond COVID-19, many analysts and investors have questioned the returns on these investments, particularly after Pfizer (NYSE: NYSE:PFE ) recently had to recall a sickle cell drug it acquired in the $5 billion Global Blood Therapeutics acquisition. The drug Oxbryta, which brought in only $300 million last year, had to be pulled due to safety concerns, further denting investor confidence. Starboard’s approach reportedly includes reaching out to Ian Read, Pfizer’s former CEO, and Frank D’Amelio, its former CFO, both of whom had a more disciplined focus on cost management and investment in novel drugs during their tenure. Under Read, Pfizer shares more than doubled, while Bourla’s leadership has coincided with a significant erosion in shareholder value. To address these challenges, Pfizer (NYSE: NYSE:PFE ) has already initiated a $4 billion cost-cutting program and is planning further reductions. However, more than $100 billion in shareholder value has evaporated since the peak of the pandemic, putting immense pressure on management to act swiftly. Technical Outlook From a technical perspective, Pfizer’s stock has been in a downward trend since its pandemic highs in 2021. However, the recent news of Starboard’s involvement has injected new life into the stock, which is up around 3% in premarket trading. This spike is also above key moving averages, suggesting a potential shift in momentum. The (Relative Strength Index) RSI currently sits at 42.59, which is just below neutral territory. While not yet in the overbought range, this indicates the stock still has room to run, particularly as investor sentiment improves following the Starboard news. The RSI suggests that the stock may be exiting its oversold condition, aligning with a bullish outlook. Pfizer has been trading in a falling trend pattern, characterized by lower highs and lower lows. However, the recent surge in premarket trading suggests a potential break from this pattern. If the stock can maintain its momentum and break through key resistance levels, we could see a reversal in its overall trend. NYSE:PFE has moved above several key moving averages, which often serve as support and resistance levels. Breaking above these averages can be a bullish signal for traders, especially in combination with improving fundamentals driven by Starboard’s involvement. Market Performance vs. Peers Pfizer's shares have been relatively flat in 2024, underperforming the broader market, which has seen a 21% rise in the S&P 500. This poor performance is in part due to fading COVID-19-related revenues and costly acquisitions that have yet to yield significant returns. The company’s stock is currently about 50% below its pandemic peak. However, it’s worth noting that while Pfizer (NYSE: NYSE:PFE ) has underperformed, it still maintains a massive market capitalization, and its core pharmaceutical business remains strong. The company’s portfolio includes blockbuster drugs and a robust pipeline of potential therapies, particularly in oncology. Should Starboard’s involvement lead to a more disciplined approach to M&A and cost management, Pfizer could be well-positioned for a resurgence. Outlook: Can Starboard Revive Pfizer? While it’s too early to say definitively what Starboard's exact plans are for Pfizer, the involvement of an activist investor of this magnitude is often a positive signal for shareholders. Starboard has historically been successful in unlocking value in companies, and if Pfizer’s management is willing to make the necessary changes, we could see a significant turnaround in its stock price.
NYSE:PFELong
by DEXWireNews
Pfizer Wins $107.5 Million From AstraZeneca in US Cancer DrugPfizer ( NYSE:PFE ) has won $107.5 million in damages from AstraZeneca in a US cancer drug patent trial. A Delaware federal jury found that AstraZeneca's lung cancer drug Tagrisso violated its Wyeth unit's patent rights. The jury agreed that AstraZeneca's drug infringed two patents covering methods for treating cancer with the breast-cancer drug Nerlynx, which is sold by Puma Biotechnology. Puma licenses the patents from Pfizer ( NYSE:PFE ) to make its drug. AstraZeneca, which earned AstraZeneca nearly $5.8 billion in revenue last year, denied infringing the patents and argued they are invalid. Pfizer ( NYSE:PFE ) is no longer a plaintiff in the case. A separate bench trial on some of AstraZeneca's remaining defenses is set to be held in June, which could result in a ruling that negates the verdict. Technical Outlook Pfizer ( NYSE:PFE ) closed Friday's trading at $28.64 down by 0.97%. The stock has a Relative Strength Index (RSI) of 64.11 which is liable for further growth. Pfizer ( NYSE:PFE ) stock is set to rise from its Falling Wedge Pattern which started from the 6th of January, 2024.
NYSE:PFE
by DEXWireNews
Pfizer Surges as Earnings Soar Above ExpectationsPfizer Inc. ( NYSE:PFE ) sent shockwaves through the market with a stunning first-quarter performance, catapulting its stock price upward following a robust quarterly beat that surpassed analysts' expectations by a wide margin. The pharmaceutical giant reported adjusted earnings of 82 cents per share, significantly outpacing the forecasted 51 cents per share, and raking in $14.88 billion in revenue, well above the anticipated $13.87 billion. This impressive feat marks a stark turnaround from the previous year's earnings of $1.23 per share on $18.49 billion in sales. Investors reacted positively to Pfizer's optimistic outlook for the year, as the company raised its earnings guidance and maintained its sales forecast. With a projected adjusted profit range of $2.15 to $2.35 per share and sales expected to reach between $58.5 billion and $61.5 billion, Pfizer is poised for a strong fiscal year ahead. Key drivers behind Pfizer's stellar performance include aggressive cost-cutting measures and resilient demand for its COVID-19 products, particularly its vaccine Comirnaty, developed in collaboration with BioNTech. Despite a significant drop in sales of the oral antiviral Paxlovid, which fell 50% to $2.04 billion, Pfizer remains optimistic about the prospects of its COVID portfolio, expecting $8 billion in combined sales from its COVID-19 products. The success of Pfizer's strategic acquisitions, notably the $43 billion deal for Seagen, is evident in the robust sales of cancer treatment Padcev and the continued growth of its pipeline. However, challenges persist, as sales of targeted cancer therapy Adcetris fell short of expectations, underscoring the need for sustained new launch performance. Attention is also focused on Pfizer's RSV vaccine, which has faced stiff competition from a rival shot by GSK. Despite lower-than-anticipated sales of Abrysvo, Pfizer ( NYSE:PFE ) remains committed to advancing its respiratory syncytial virus (RSV) vaccine portfolio. Analysts remain cautiously optimistic about Pfizer's trajectory, with JP Morgan's Chris Schott emphasizing the importance of stronger new launch performance and pipeline progress in reshaping investor sentiment.
NYSE:PFE
by DEXWireNews
FDA Approves Pfizer’s First Gene TherapyIn a landmark decision, the Food and Drug Administration (FDA) has given its stamp of approval to Pfizer's groundbreaking gene therapy for hemophilia B, marking a pivotal moment in the field of genetic medicine. Hemophilia B, a rare inherited bleeding disorder affecting thousands in the U.S., has long posed significant challenges for patients and caregivers due to its debilitating nature and the cumbersome treatment regimens it necessitates. Unveiling Beqvez: Pfizer's newly approved gene therapy, Beqvez, heralds a paradigm shift in hemophilia B treatment. Unlike conventional methods that require frequent infusions of factor IX, Beqvez offers a one-time solution, empowering patients to produce the crucial clotting factor independently. This innovative approach not only promises to alleviate the burden of regular treatments but also holds the potential to prevent and control bleeding more effectively. Transformative Impact: The approval of Beqvez represents a ray of hope for individuals grappling with hemophilia B, offering a lifeline towards improved quality of life and reduced medical complexities. Dr. Adam Cuker, from Penn Medicine’s Comprehensive and Hemophilia Thrombosis Program, underscores the transformative potential of Beqvez, emphasizing its ability to mitigate both medical and treatment-related challenges over the long term. Pfizer's Strategic Maneuver For Pfizer ( NYSE:PFE ), the approval of Beqvez marks a strategic triumph in its quest to diversify beyond the realm of COVID therapeutics. With a keen focus on gene and cell therapies, Pfizer ( NYSE:PFE ) is positioning itself at the forefront of medical innovation, aiming to redefine the treatment landscape across various disease domains. The company's investment in Beqvez underscores its commitment to pioneering solutions that address unmet medical needs and enhance patient outcomes. Navigating Challenges: While the approval of Beqvez heralds a new era in hemophilia B treatment, it also presents formidable challenges. The exorbitant price tag of $3.5 million raises concerns about accessibility and affordability, echoing debates surrounding the broader issue of healthcare equity. Furthermore, logistical hurdles and adoption barriers may impede widespread uptake, underscoring the need for comprehensive strategies to ensure equitable access to this groundbreaking therapy. Looking Ahead: As Pfizer ( NYSE:PFE ) embarks on this groundbreaking journey with Beqvez, the company's pipeline continues to brim with promise. From experimental antibodies to gene therapies targeting other genetic disorders like Duchenne muscular dystrophy, Pfizer remains at the vanguard of medical innovation, driving forward the frontier of personalized medicine. As the healthcare landscape evolves, Beqvez stands as a beacon of hope, illuminating a path towards a future where genetic therapies revolutionize the treatment paradigm, one patient at a time.
NYSE:PFELong
by DEXWireNews
$PFE (Pfizer Inc) - Double Bottom and Missing RetestIt seems like the price may have hit its bottom, as we're seeing two Key Reversals on the Monthly timeframe. This scenario could signal a Double Bottom, setting the stage for a high-probability trade setup with waiting for the price to break through the recent Lower High (LH) to confirm a change in trend. Shifting our focus to the Daily timeframe, there are few potential Sniper Entries opportunities offering the promise of substantial rewards 💸
NYSE:PFELong
by Dragon_Ball
Pfizer - Watch The SupportHello Traders, welcome to today's analysis of Pfizer. -------- Explanation of my video analysis: All the way back in 2012 Pfizer created a massively bullish triangle reversal pattern at the $17.00 level. This was followed by a +200% rally. Since 2022 Pfizer has been dropping significantly and is now retesting the support level which I mentioned in the analysis. If we see bullish conformation on the smaller timeframes, this might be an interesting long trading setup. -------- I will only take a trade if all the rules of my strategy are satisfied. Let me know in the comment section below if you have any questions. Keep your long term vision.
NYSE:PFE
by basictradingtv
7
Health Canada Approval of ABRYSV Paves the Way for Pfizer In a significant stride towards enhancing public health, Health Canada has recently granted approval for Pfizer's groundbreaking bivalent Respiratory Syncytial Virus (RSV) vaccine, ABRYSVO™. This development is a crucial step in safeguarding both older adults and infants through maternal immunization. With the potential to revolutionize preventive healthcare, ABRYSVO™ addresses the prevention of lower respiratory tract diseases caused by RSV, catering to individuals aged 60 and above and infants from birth through 6 months. Protecting the Vulnerable Populations: The approval of ABRYSVO™ presents a new and vital option for protecting individuals most susceptible to severe RSV infections. Infants, particularly those under one year, face an increased risk of hospitalization due to RSV infection. Older adults also bear a significant burden of costs associated with the disease. Pfizer's vaccine aims to provide a comprehensive solution, mitigating the impact of RSV across different age groups and reducing the strain on healthcare resources. Maternal Immunization as a Strategic Approach: Dr. Darine El-Chaâr, a Maternal Fetal Medicine physician at The Ottawa Hospital, emphasizes the critical role of maternal immunization in bridging the vulnerability gap during the first few months of an infant's life. By administering vaccines to pregnant individuals, the approach not only protects the newborns but also safeguards mothers who may face an increased risk of severe disease compared to non-pregnant women. This strategic approach aligns with Pfizer's commitment to making a positive contribution to public health and community well-being. Pfizer's Commitment to Public Health: Andréa Mueller, Primary Care Portfolio Lead at Pfizer Canada, expresses pride in Pfizer's decades-long experience in vaccine development. The company's commitment to public health is evident in its dedication to providing effective solutions for preventing illness and reducing the strain on healthcare systems. The approval of ABRYSVO™ represents Pfizer's ongoing commitment to advancing healthcare solutions and making a positive impact on global well-being. Market Analysis: While the approval of ABRYSVO™ marks a significant milestone for Pfizer's contribution to public health, the technical analysis of Pfizer's stock indicates a falling trend channel in the medium to long term. Investors appear to have sold at lower prices over time, reflecting negative sentiments towards the company. However, it's essential to note that market trends are dynamic, and the approval of a groundbreaking vaccine may influence investor perceptions in the future. Conclusion: Pfizer's Health Canada approval for ABRYSVO™ brings hope for enhanced protection against RSV infections, benefiting both older adults and infants. The strategic focus on maternal immunization highlights Pfizer's commitment to addressing healthcare challenges comprehensively. As the company works towards making ABRYSVO™ available to Canadians, the market will likely closely watch how this groundbreaking vaccine contributes not only to public health but also to Pfizer's future trajectory in the pharmaceutical landscape.
NYSE:PFE
by DEXWireNews
Pfizer (PFE) -> It Is Now Or NeverMy name is Philip, I am a German swing-trader with 4+ years of trading experience and I only trade stocks , crypto , options and indices 🖥️ I only focus on the higher timeframes because this allows me to massively capitalize on the major market swings and cycles without getting caught up in the short term noise. This is how you build real long term wealth! In today's anaylsis I want to take a look at the bigger picture on Pfizer. At the moment Pfizer stock is once again retesting major sructure at the psychological $33 level which already acted as pretty strong support in the past. Considering that the next support level below current price is at $27, Pfizer is now trading at a pretty decisive potential turning point and has not yet broken structure towards the downside. - - - - - - - - - - - - - - - - - - - - I know that this is a quite simple trading approach but over the past 4 years I've realized that simplicity and consistency are much more important than any trading strategy. Keep the long term vision🫡
NYSE:PFELong
by basictradingtv
20
Accumulating PFE from $46.00 - $47.50 This is one of the stocks I hold indefinitely for dividends. we're at the bottom of our current channel and a double bottom is forming in a major area of support. In my previous post I stated my accumulation sections are in the lower end of the channel, so this is prime real estate to enter. Momentum downwards has come to a halt and I believe we will retest the center channel line from this point. I am diversifying a portion of profits I made from the last 2 trade set ups I've posted into PFE. A fundamentally sound entity in our current market economy. I'm sure you could assume why.
NYSE:PFELong
by WatsonsView
Pfizer | Fundamental Analysis | MUST READ | LONG 🔔Historically, Pfizer has not had much momentum when it comes to stock performance. Over the past ten years, the S&P 500 Index has outperformed this large pharmaceutical company. But now Pfizer is gaining momentum. Last year it outperformed the benchmark index - Pfizer was up 60%, while the S&P 500 was up 27%. And today's Pfizer doesn't look much like Pfizer did a few years ago. In 2020, the company completed the separation of its Upjohn business, eliminating an element that was driving down revenues. Today, Pfizer has many "best sellers," a new coronavirus drug, and a full development cycle. So is it worth investing in this drug maker in 2022? First, let's look at the company's Covid business. Pfizer is a leading supplier of vaccines in many parts of the world. In the U.S., the company has fully vaccinated more than 118 million people. But overseas, Pfizer's vaccine business is actually even bigger. The company claims that it generates 75% of its revenues from vaccine sales outside the United States. The European Union recently exercised an option to supply more Pfizer vaccines, bringing the total number of doses of Pfizer vaccines to be delivered this year to over 650 million. The full agreement, signed last spring, calls for up to 1.8 billion doses to be delivered to the region by 2023. In Pfizer's latest earnings report, the company projected vaccine revenue of $36 billion for all of 2021. But this year could turn out to be even more successful for Pfizer than last year. Here's why. Vaccine orders remain high -- but with the addition of a new coronavirus product. Late last year, Pfizer received approval for the emergency use of Paxlovid, an oral coronavirus treatment. Paxlovid is a pill that should be given at the first sign of infection. The drug's main ingredient blocks the action of an enzyme necessary for the coronavirus replication process. The U.S. has ordered 20 million courses of Paxlovid treatment, and the U.K. has ordered 2.75 million. SVB Leerink analyst Geoffrey Porges predicts that Paxlovid will generate more than $24 billion in revenue this year and $29.7 billion in vaccines, according to FiercePharma. That amounts to more than $50 billion in revenue from the coronavirus program alone. Of course, investors are most concerned about what will happen to these revenues in a post-pandemic world. Right now, it's impossible to accurately predict the level of revenue from the coronavirus program in the future. And that represents uncertainty. Nevertheless, experts say the coronavirus will exist. And that means we will need remedies and treatments. So we can probably expect a satisfactory level of revenue from coronavirus-related products for quite some time. But here's the best news: Pfizer is far from being a coronavirus-only company. The company's nine-month earnings report shows that at least six products are generating blockbuster revenue. And in the third quarter, the company says, revenue excluding the coronavirus vaccine rose 7 percent to more than $11 billion. As if that weren't enough, Pfizer has something else to like. And that's the pipeline. The company is working on 94 programs -- 29 of which are in Phase 3 and nine of which are in the registration phase. That means we may see a new batch of drugs in the not-too-distant future. This is important because the patent on some of Pfizer's drugs expires at the end of this decade. The blood-thinning drug Eliquis, for example, will lose protection in 2028. This is a standard part of life for a pharmaceutical company - and that's why it's important to have a strong product portfolio to make up for future patent expirations. Now let's look at the valuation. As mentioned earlier, Pfizer's stock price has risen slightly. But it is still trading at very reasonable levels. It trades at only 8.5 times projected earnings. In addition, Pfizer pays a solid dividend, with a yield of over 2.8%. So should you invest in Pfizer in 2022? Well, now seems like a good time to do so. The company generates billions of dollars in revenue from its coronavirus vaccine program. It has a portfolio of non-coronavirus drugs and a full cycle of late-stage research. The stock looks inexpensive -- and an investment in this major pharmaceutical player will provide you with passive income in the form of dividends. All of this is a great formula for success this year and in the years to come.
NYSE:PFELong
by FOREXN1
4
PFE Pfizer to All Time HighIf you haven`t bought at my first call, when PFE was $40: Than you should know that Pfizer’s vaccine with BioNTech SE is on track to be the best-selling drug product on a yearly basis and received backing from a European regulatory panel on Thursday to expand its use into children as young as five. Still low PE Ratio (TTM) 15.42 Decent Forward Dividend & Yield 1.56 (2.89%) The stock jumped also on the promise of its antiviral pill! For me is a Buy even at this level!
NYSE:PFELong
by TopgOptions
1